Eight African countries have reportedly begun receiving shipments of the HIV-prevention injection lenacapavir, a twice-yearly drug priced at about $40 per person annually, in a move health officials say could reshape efforts to curb infections in the region hardest hit by the virus.
Gilead said last November it had delivered the first supplies of the injectable pre-exposure prophylaxis, or PrEP, to Eswatini and Zambia. Shipments have since expanded to South Africa, Zimbabwe, Kenya, Lesotho, Uganda and Nigeria, according to health officials and program partners.